Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

The Genetic Background of Heart Failure and the Role of Hypertension

29.04.2008
Researchers from Berlin, Germany have identified variations in a gene, which contributes to heart failure in the presence of hypertension.

The gene, Ephx2, encodes an enzyme (soluble epoxide hydrolase) that normally degrades specific epoxides. In this case, the epoxides can be cardioprotective in the setting of heart failure but not necessarily relevant for healthy individuals. In persons with heart failure, a low Ephx2 activity would not break down the epoxides and as a result, the heart could be protected from further damage.

However, in persons with both heart failure and an altered Ephx2 gene resulting in a hyperactive soluble epoxide hydrolase, the epoxides would be degraded. This state-of-affairs would worsen the heart failure condition. The Ephx2 gene was identified by the physicians Dr. Jan Monti, Prof. Friedrich Luft (both Charité-Universitätsmedizin Berlin/Helios Klinikum Berlin-Buch), and the genome researcher Prof. Norbert Hübner (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch), as well as by their collaborators. The results were published online in the current issue of the journal Nature Genetics (Vol. 40, No. 5, pp. 529 - 537, 2008)*. The scientists hope that their results might improve the diagnosis and therapy for heart failure.

According to the American Heart Association, more than 57,000 Americans died of heart failure in 2004. The number of Europeans is larger still. Heart failure is the third most common cause of death in Western countries, after coronary heart disease and stroke. Heart failure commonly results from coronary disease and hypertension.

Heart failure usually develops over a longer period of time and is therefore commonly seen in older individuals. When the heart is no longer able to pump enough blood to meet the body's requirements, the heart muscle enlarges in an effort to compensate. However, often the heart does not overcome the increased burden and becomes weakened further, especially in cases of pre-existing hypertension. "But elevated blood pressure does not necessarily cause heart failure in all patients," Dr. Monti, physician at the Charité and Helios, explains. "Hypertension damages the heart and increases the propensity to develop heart failure. Other factors also contribute to the disease."

The spontaneously hypertensive stroke-prone (SHRSP) rat strain, which is characterized by severe hypertension, does not develop heart failure. In contrast, the spontaneously hypertensive heart failure (SHHF) rat strain regularly develops heart failure as a result of hypertension. The investigators capitalized on these observations to answer the question, "why?" When comparing both strains, the researchers observed that SHHF rats possess genetic variations that are not present in SHRSP rats. These single base pair variations are called "single nucleotide polymorphisms" (SNPs). "In SHHF rats, SNPs in the gene called Ephx2 lead to an increased production of the enzyme soluble epoxide hydrolase," Prof. Hübner explains. He is the genome researcher from the MDC who conceived the project.

The body's "self aid" drops out
"In a healthy person, the soluble epoxide hydrolase degrades the body's own substances (epoxides). Some epoxides can protect the heart from damage. When the heart is overloaded, as occurs in hypertension, we would like the epoxides to be able to fulfil their supporting tasks to the utmost. However, the genetic variation we observed in the SHHF rats prevents downregulation of the enzyme", Prof. Hübner remarks further. "Because of the variation, the soluble epoxide hydrolase is still active during overload of the heart. The epoxides that are sorely needed are degraded. Thus, the body's "self aid" drops out," he says. "Without epoxides, the heart is more prone to develop heart failure when blood pressure is high."

The soluble epoxide hydrolase was long suspected to play a role in the development of heart failure. "But a candidate gene is not a proof", notes Prof. Luft. "It took more than four years for numerous researchers working together to gather convincing evidence about the candidate gene." Clinicians and scientists now hope for the development of new diagnostic and therapeutic options. "Animal experiments with inhibitors of the soluble epoxide hydrolase are in progress," Dr. Monti comments. "However, a gene deletion in a mouse is not necessarily the same as an inhibitory drug. The way into the clinical arena is long and arduous."

*Soluble epoxide hydrolase is a susceptibility gene for heart failure in a rat model of human disease

Jan Monti1,2,9, Judith Fischer1,9, Svetlana Paskas1, Matthias Heinig1,3, Herbert Schulz1, Claudia Gösele1, Arnd Heuser1,2, Robert Fischer1,2, Cosima Schmidt1, Alexander Schirdewan2, Volkmar Gross1, Oliver Hummel1, Henrike Maatz1, Giannino Patone1, Kathrin Saar1, Martin Vingron3, Steven M Weldon4, Klaus Lindpaintner5, Bruce D Hammock6, Klaus Rohde1, Rainer Dietz1,2, Stuart A Cook7, Wolf-Hagen Schunck1, Friedrich C Luft1,8 & Norbert Hubner1

1Max-Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125 Berlin, Germany. 2Department of Clinical and Molecular Cardiology, Franz-Volhard Clinic, HELIOS, Charite´ -Universitätsmedizin Berlin, Schwanebecker Chaussee 50, 13125 Berlin, Germany. 3Department of Bioinformatics, Max-Planck-Institute for Molecular Genetics, Ihnestraße 63-73, 14195 Berlin, Germany. 4Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368, USA. 5F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland. 6Departments of Entomology and Nutrition and Cancer Research Center, University of California at Davis, One Shields Avenue, Davis, California 95616-8584, USA. 7MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ, UK. 8Department of Nephrology/Hypertension, Franz-Volhard Clinic, HELIOS, Charité -Universitätsmedizin Berlin, Schwanebecker Chaussee 50, 13125 Berlin, Germany. 9These authors contributed equally to this work.

Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10; 13125 Berlin; Germany
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
e-mail: presse@mdc-berlin.de

Barbara Bachtler | Max-Delbrück-Centrum
Further information:
http://www.mdc-berlin.de/en/news

Further reports about: Ephx2 Epoxide Genetic SHHF heart failure hydrolase hypertension soluble

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>